|
| Ref. | Expression/Function | Targets |
|
| Mouse | |
| [5] | Differential expression in Th1/Th2 cells | |
| [10] | Impaired Treg function in mice lacking miR-146a | STAT1 |
| [11] | Provided protection from bacteria induced epithelial damage in neonates | IRAK1 |
|
| Human | |
| [12] | Attenuated TLR4 signaling in monocytes | IRAK1, TRAF6 |
| [13] | Regulated activation induced cell death and IL-2 expression in Jurkat T cells | FADD |
| [14] | Contributed to the establishment of endotoxin tolerance in monocytes | IRAK1, TRAF6 |
| [15] | Desensitized Langerhans cells to inappropriate TLR signaling | |
| [16] | Negatively regulated inflammatory response in lung epithelial cells | |
| [17] | Controlled megakaryopoiesis | CXCR4 |
| [18] | Reduced migration and invasion capacity of breast cancer cells | IRAK1, TRAF6 |
| [19] | Promoted cell proliferation in cervical cancer | |
| [20] | Tumor suppressor in hormone-refractory prostate cancer | ROCK1 |
| [21] | Suppressed invasion of pancreatic cancer cells | EGFR, IRAK1 |
| [22] | SNP in pre-miR-146a predisposes to papillary thyroid carcinoma | |
|
| Viruses | |
| [23] | Promoted VSV replication in macrophages | IRAK1, IRAK2, TRAF6 |
| [24] | EBV-encoded LMP1 induced cellular miR-146a expression | |
|